Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
Co-administration with ergot alkaloids (see Interactions).
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see Precautions and Interactions).
Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin (see Interactions).
Co-administration during the initiation and dose-titration phase of venetoclax in Chronic Lymphocytic Leukaemia (CLL) patients (see Precautions and Interactions).
